Hormone Replacement Therapy Market will grow at a CAGR of 5.5% to surpass US$ 16.62 Billion by 2026

New mergers and acquisitions is one of the major factor driving the growth of the hormone replacement therapy market. For instance, in 2014, Pfizer Inc., a U.S.-based pharmaceutical company, merged with OPKO Health Inc., a U.S.-based company, to develop a long acting growth hormone (hGH-CTP) and innovative treatments for growth hormone deficient patients. hGH-CTP is more convenient, as the patients need to take just one injection in a week rather than daily doses. hGH-CTP has an orphan drug designation in the U.S. and Europe for adults and children with growth hormone deficiency.

The global hormone replacement therapy market size was valued at US$ 10.58 billion in 2017 and is expected to witness a CAGR of 5.2% over the forecast period (2018 - 2026).

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-sample/2079

Robust pipeline is also expected to support growth of the hormone replacement therapy market size. For instance, Somapacitan sponsored by Novo Nordisk A/S, a Denmark-based company, completed phase 3 clinical trials in 2017. This drug is used for the treatment of growth hormone deficiency in adults.

Manufacturers are focusing on developing generic versions of various drugs for the treatment of certain disorders that are highly prevalent in women such as hypothyroidism. For instance, Teva Pharmaceutical Industries Ltd. launched generic version of Vagifem (estradiol vaginal inserts), 10 mcg in the U.S. on 24, July 2017. Estradiol vaginal inserts are an estrogen indicated for the treatment of atrophic vaginitis due to menopause.

Moreover, on December 29, 2017, Mylan N.V. got the U.S. FDA approval for its Abbreviated New Drug Application (ANDA) for Estradiol Vaginal Cream USP, 0.01% and thus, the company launched this drug in the U.S. This cream is the first generic version of Allergan's Estrace Cream, indicated for the treatment of vulvar and vaginal atrophy.

Mylan is one of the few companies that offers Estradiol in four delivery systems - cream, gel, transdermal patch, and tablet. This provides greater benefit to healthcare professionals and patients, and brings long-term sustainability to their business.

Ask for sample copy @ https://www.coherentmarketinsights.com/insight/request-sample/2079

Key players operating in the global hormone replacement therapy market include Novartis AG, Abbott Laboratories, Mylan N.V., Merck KgaA, Bayer AG, Pfizer Inc., Novo Nordisk A/S, QuatRx Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Amgen, Inc., and Eli Lilly and Company.

1001 4th Ave,, #3200, Seattle, WA 98154

About CoherentmarketInsights
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients in achieving transformational growth and making critical business decisions. We are headquartered in India, with an office in the global financial capital in the U.S. Our client base includes players across all busi-ness verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends, and new working methods. We offer both customized and syndicated mar-ket research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various in-dustries at both, global and regional levels, to identify new opportunities for our cli-entele. Our global team of over 100 research analysts and freelance consultants provides market intelligence from the molecular country level, and also provides a global perspective of the market. Our team is the most vital cog in our robust ma-chinery that gives us the ability to deliver independent insights through our cognitive defusion training module. This ensures an objective and unbiased assessment of the market. We are constantly striving to update our extremely in-depth understanding of the market by closely monitoring and analyzing markets, trends, and emerging best practices across all fathomable industries under the sun. This enables us to equip our valued clientele with key decisive inputs to capitalize on lucrative growth opportunities in the market, and to firmly position themselves on a higher growth path in the future.

This release was published on openPR.